Clinical Trial Update: Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating a neratinib dose escalation regimen for HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• neratinib (neratinib)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN